Last Friday (10/3), our Vice President Jennifer Che met with Grace S N Lau of the Institute for Translational Research of HKSTP and the HKSTP community to discuss the fundamentals of IP and how “common” early-stage business/R&D activities can hurt your IP.




Our Past Events

Jennifer Che has been Recognized in IAM Strategy 300 Global Leaders 2026

26 November 2025

Jennifer Che has been Recognized as IAM Global Leaders 2026

4 November 2025

Eagle IP is Coming to San Francisco and Washington DC!

15 October 2025

Jennifer Che has been listed on the IAM Strategy 300

15 August 2025

Eagle IP Recognized as Top Tier Firm (Tier 1) for Patent Prosecution in IP Stars 2025 Patent Firms Ranking List

3 July 2025

Dr. Jacqueline Lui, Ms. Pauli Wong, and Mr. Eddie Ho Named Patent Stars by ManagingIP

13 June 2025

Recommended Insights

CNIPA Releases Interim Measures for the Amended Chinese Patent Law Going Into Effect June 1, 2021

28 May 2021
Breaking News! We finally have more details about the new Chinese Patent Law which will go into effect on June 1, 2021. The full set of measure can be found at this link. Below are some pertinent points. No Implementation Rules . . . . Yet The new Implementation Rules will not be available by […]
Read more >

Do Promotional Marketing Materials Constitute an “Offer for Sale” under Chinese Patent Law? Bayer IP GmbH v. Nanjing Hang Seng Pharmaceutical

12 December 2023
Bayer's blockbuster drug Rivaroxaban has seen its share of patent litigations in China, several of which are big enough to be listed as Top 10 IP cases or 50 Representative IP cases. We summarized an invalidation case back in 2020 where all of Bayer’s claims directed towards the compound were upheld. Recently, another Rivaroxaban case […]
Read more >

CHINA: New Patent Examination Guidelines Now Available for Public Comment

4 August 2021
Two months after the new Chinese Patent law came into effect, the CNIPA has released a new set of Patent Examination Guidelines (proposed version) for public comments on Aug 3, 2021. Here are the explanation of the amendments (Chinese only). Here is the full set of proposed amendments (Chinese only). Briefly, the new amendment focuses […]
Read more >

China’s Newest Examination Guidelines: Inventive Step for Biological / Life Science Inventions (Part III)

30 April 2021
This is Part III of a three-part series summarizing the Examination Guidelines that were released by the CNIPA on January 15, 2021, one year to the date of Phase 1 of the US and China Economic and Trade Agreement. That agreement included specific provisions where China "shall permit pharmaceutical patent applicants to rely on supplemental […]
Read more >
Top crossarrow-right